Dopaminergic neuron metabolism: relevance for understanding Parkinson’s disease.

Dopaminergic neuron metabolism: relevance for understanding Parkinson’s disease.

Publication date: Oct 13, 2024

Dopaminergic neurons from the substantia nigra pars compacta (SNc) have a higher susceptibility to aging-related degeneration, compared to midbrain dopaminergic cells present in the ventral tegmental area (VTA); the death of dopamine neurons in the SNc results in Parkinson’s disease (PD). In addition to increased loss by aging, dopaminergic neurons from the SNc are more prone to cell death when exposed to genetic or environmental factors, that either interfere with mitochondrial function, or cause an increase of oxidative stress. The oxidation of dopamine is a contributing source of reactive oxygen species (ROS), but this production is not enough to explain the differences in susceptibility to degeneration between SNc and VTA neurons. In this review we aim to highlight the intrinsic differences between SNc and VTA dopamine neurons, in terms of gene expression, calcium oscillations, bioenergetics, and ROS responses. Also, to describe the changes in the pentose phosphate pathway and the induction of apoptosis in SNc neurons during aging, as related to the development of PD. Recent work showed that neurons from the SNc possess intrinsic characteristics that result in metabolic differences, related to their intricate morphology, that render them more susceptible to degeneration. In particular, these neurons have an elevated basal energy metabolism, that is required to fulfill the demands of the constant firing of action potentials, but at the same time, is associated to higher ROS production, compared to VTA cells. Finally, we discuss how mutations related to PD affect metabolic pathways, and the related mechanisms, as revealed by metabolomics.

Open Access PDF

Concepts Keywords
Bioenergetics Aging
Dopaminergic Animals
Genetic Complex axonal arborization
Increase Dopamine
Parkinsons Dopamine
Dopaminergic Neurons
Energy Metabolism
Humans
Metabolic alterations
Mitochondria
Neurodegeneration
Oxidative Stress
Pacemaking activity
Parkinson Disease
Pars Compacta
Reactive Oxygen Species
Reactive Oxygen Species
ROS production
Ventral Tegmental Area

Semantics

Type Source Name
pathway REACTOME Metabolism
disease MESH Parkinson’s disease
disease MESH death
drug DRUGBANK Dopamine
disease MESH oxidative stress
drug DRUGBANK Calcium
pathway REACTOME Pentose phosphate pathway
pathway KEGG Metabolic pathways
drug DRUGBANK D-Alanine
drug DRUGBANK Flunarizine
drug DRUGBANK Ilex paraguariensis leaf
drug DRUGBANK Oxygen
pathway REACTOME Apoptosis
disease MESH resting tremor
disease MESH muscular rigidity
disease MESH gait
disease MESH mitochondria dysfunction
drug DRUGBANK ATP
drug DRUGBANK Dextrose unspecified form
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Adenosine 5′-phosphosulfate
drug DRUGBANK Ubiquinol
pathway REACTOME Glycolysis
drug DRUGBANK Isradipine
pathway REACTOME Glucose metabolism
drug DRUGBANK Nitric Oxide
drug DRUGBANK Fructose
pathway KEGG Oxidative phosphorylation
drug DRUGBANK Coenzyme M
pathway KEGG Peroxisome
drug DRUGBANK Glutathione
drug DRUGBANK Phosphate ion
drug DRUGBANK 1-naphthaleneacetic acid
drug DRUGBANK Choline
drug DRUGBANK Glutamic Acid
drug DRUGBANK Glycine
drug DRUGBANK Trihexyphenidyl
drug DRUGBANK Profenamine
disease MESH tumor
drug DRUGBANK Phosphoenolpyruvate
drug DRUGBANK Methionine
pathway REACTOME Pyruvate metabolism
pathway REACTOME Autophagy
disease MESH hypoxia
drug DRUGBANK Succinic acid
drug DRUGBANK Glutathione disulfide
pathway KEGG Glutathione metabolism
disease MESH defects
drug DRUGBANK NADH
drug DRUGBANK Creatine
drug DRUGBANK Taurine
drug DRUGBANK gamma-Aminobutyric acid
drug DRUGBANK L-Glutamine
drug DRUGBANK Glypromate
drug DRUGBANK L-Lysine
disease MESH PGK1 deficiency
disease MESH pathogenesis
disease MESH parkinsonism
pathway KEGG Parkinson disease
pathway REACTOME Reproduction
disease MESH syndrome
disease MESH MPTP Induced parkinsonism
disease MESH tics
disease MESH Central Nervous System diseases
drug DRUGBANK Nandrolone phenpropionate
disease MESH neurodegenerative disorders
pathway KEGG Lysosome
drug DRUGBANK Bean
drug DRUGBANK L-Aspartic Acid

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *